Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:872-880
Published online before print January 29, 2007, doi: 10.1161/CIRCULATIONAHA.106.667675
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
115/7/872    most recent
CIRCULATIONAHA.106.667675v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knaus, A.
Right arrow Articles by Hein, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knaus, A.
Right arrow Articles by Hein, L.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Genetically altered mice
Right arrow Ion channels/membrane transport
Right arrow Autonomic, reflex, and neurohumoral control of circulation

(Circulation. 2007;115:872-880.)
© 2007 American Heart Association, Inc.


Arrhythmia/Electrophysiology

Direct Inhibition of Cardiac Hyperpolarization-Activated Cyclic Nucleotide–Gated Pacemaker Channels by Clonidine

Anne Knaus*; Xiangang Zong, MD*; Nadine Beetz; Roland Jahns, MD; Martin J. Lohse, MD; Martin Biel, PhD; Lutz Hein, MD

From the Department of Pharmacology and Toxicology (A.K., R.J., M.J.L.) and Department of Internal Medicine (R.J.), University of Würzburg, Würzburg, Germany; Department of Pharmacy–Center for Drug Research (X.Z., M.B.), Ludwig Maximilian University of Munich, München, Germany; and Institute of Experimental and Clinical Pharmacology and Toxicology (A.K., N.B., L.H.), University of Freiburg, Freiburg, Germany.

Correspondence to Lutz Hein, MD, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Albertstrasse 25, 79104 Freiburg, Germany. E-mail lutz.hein{at}pharmakol.uni-freiburg.de

Received October 1, 2006; accepted December 15, 2006.

Background— Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure. Activation of presynaptic {alpha}2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.

Methods and Results— To test whether clonidine elicits pharmacological effects independent of {alpha}2-adrenoceptors, we have generated mice with a targeted deletion of all 3 {alpha}2-adrenoceptor subtypes ({alpha}2ABC–/–). {alpha}2ABC–/– mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in {alpha}2ABC–/– mice by up to 150 bpm. Clonidine-induced bradycardia in conscious {alpha}2ABC–/– mice was 32.3% (10 µg/kg) and 26.6% (100 µg/kg) of the effect in wild-type mice. A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from {alpha}2ABC-knockout and wild-type mice. Clonidine inhibited the native pacemaker current (If) in isolated sinoatrial node pacemaker cells and the If-generating hyperpolarization-activated cyclic nucleotide–gated (HCN) 2 and HCN4 channels in transfected HEK293 cells. As a consequence of blocking If, clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and {alpha}2ABC-knockout mice.

Conclusions— Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
N. Beetz, L. Hein, J. Meszaros, R. Gilsbach, F. Barreto, M. Meissner, U. C. Hoppe, A. Schwartz, S. Herzig, and J. Matthes
Transgenic simulation of human heart failure-like L-type Ca2+-channels: implications for fibrosis and heart rate in mice
Cardiovasc Res, December 1, 2009; 84(3): 396 - 406.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Biel, C. Wahl-Schott, S. Michalakis, and X. Zong
Hyperpolarization-Activated Cation Channels: From Genes to Function
Physiol Rev, July 1, 2009; 89(3): 847 - 885.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Biel
Cyclic Nucleotide-regulated Cation Channels
J. Biol. Chem., April 3, 2009; 284(14): 9017 - 9021.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Miyamoto, T. Kawada, Y. Yanagiya, T. Akiyama, A. Kamiya, M. Mizuno, H. Takaki, K. Sunagawa, and M. Sugimachi
Contrasting effects of presynaptic {alpha}2-adrenergic autoinhibition and pharmacologic augmentation of presynaptic inhibition on sympathetic heart rate control
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1855 - H1866.
[Abstract] [Full Text] [PDF]